Ind-Swift Limited (INDSWFTLTD.BO)
INR 28.0
(5.7%)
INR 28.0
(5.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 142.31 Million INR | -45.34% |
| 2022 | 260.36 Million INR | 230.05% |
| 2021 | -200.2 Million INR | 32.85% |
| 2020 | -298.16 Million INR | -55.93% |
| 2019 | -191.21 Million INR | -333.37% |
| 2018 | 81.93 Million INR | 115.14% |
| 2017 | -541.27 Million INR | 85.48% |
| 2016 | -3.72 Billion INR | -74.5% |
| 2015 | -2.13 Billion INR | -47.17% |
| 2014 | -1.45 Billion INR | -25.58% |
| 2013 | -1.15 Billion INR | -3.84% |
| 2012 | -1.11 Billion INR | 0.0% |
| 2010 | 434.51 Million INR | 18.35% |
| 2009 | 367.15 Million INR | -2.71% |
| 2008 | 377.38 Million INR | 20.78% |
| 2007 | 312.45 Million INR | 49.85% |
| 2006 | 208.51 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 282.39 Million INR | -24.78% |
| 2023 FY | 142.31 Million INR | -45.34% |
| 2023 Q4 | 375.39 Million INR | 350.85% |
| 2023 Q3 | -149.65 Million INR | -39.79% |
| 2023 Q2 | -107.05 Million INR | -553.16% |
| 2023 Q1 | 23.62 Million INR | -95.55% |
| 2022 Q4 | 530.95 Million INR | 5244.94% |
| 2022 Q3 | -10.32 Million INR | 90.26% |
| 2022 Q2 | -105.9 Million INR | 31.39% |
| 2022 Q1 | -154.36 Million INR | -181.57% |
| 2022 FY | 260.36 Million INR | 230.05% |
| 2021 Q3 | -67.69 Million INR | -37.18% |
| 2021 Q1 | -35.67 Million INR | 79.59% |
| 2021 Q2 | -49.35 Million INR | -38.35% |
| 2021 FY | -200.2 Million INR | 32.85% |
| 2021 Q4 | -54.82 Million INR | 19.02% |
| 2020 FY | -298.16 Million INR | -55.93% |
| 2020 Q1 | -88.62 Million INR | -87.74% |
| 2020 Q2 | -22.9 Million INR | 74.16% |
| 2020 Q3 | -11.89 Million INR | 48.06% |
| 2020 Q4 | -174.73 Million INR | -1368.85% |
| 2019 FY | -191.21 Million INR | -333.37% |
| 2019 Q3 | -117.96 Million INR | -128321.74% |
| 2019 Q4 | -47.2 Million INR | 59.98% |
| 2019 Q1 | -26.13 Million INR | -118.68% |
| 2019 Q2 | 92 Thousand INR | 100.35% |
| 2018 FY | 81.93 Million INR | 115.14% |
| 2018 Q3 | -37.32 Million INR | -31.57% |
| 2018 Q4 | 139.86 Million INR | 474.67% |
| 2018 Q2 | -28.37 Million INR | -72.51% |
| 2018 Q1 | -16.44 Million INR | 78.45% |
| 2017 Q4 | -76.29 Million INR | 45.48% |
| 2017 Q1 | -145.6 Million INR | 84.24% |
| 2017 FY | -541.27 Million INR | 85.48% |
| 2017 Q3 | -139.94 Million INR | 0.0% |
| 2016 Q1 | -256.03 Million INR | 78.69% |
| 2016 Q3 | -1.85 Billion INR | -165.33% |
| 2016 Q2 | -699.32 Million INR | -173.14% |
| 2016 Q4 | -923.8 Million INR | 50.21% |
| 2016 FY | -3.72 Billion INR | -74.5% |
| 2015 FY | -2.13 Billion INR | -47.17% |
| 2015 Q2 | -241.13 Million INR | 21.73% |
| 2015 Q4 | -1.2 Billion INR | -382.64% |
| 2015 Q3 | -248.89 Million INR | -3.22% |
| 2015 Q1 | -308.09 Million INR | 39.03% |
| 2014 Q2 | -243.08 Million INR | -16.14% |
| 2014 FY | -1.45 Billion INR | -25.58% |
| 2014 Q4 | -505.36 Million INR | -2.4% |
| 2014 Q3 | -493.53 Million INR | -103.03% |
| 2014 Q1 | -209.29 Million INR | -534.29% |
| 2013 Q2 | -413.95 Million INR | 1.42% |
| 2013 FY | -1.15 Billion INR | -3.84% |
| 2013 Q1 | -419.91 Million INR | -7.71% |
| 2013 Q3 | -369.95 Million INR | 10.63% |
| 2013 Q4 | 48.19 Million INR | 113.03% |
| 2012 Q4 | -389.84 Million INR | 13.32% |
| 2012 FY | -1.11 Billion INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | -273.29 Million INR | 0.0% |
| 2012 Q3 | -449.73 Million INR | -64.56% |
| 2010 FY | 434.51 Million INR | 18.35% |
| 2009 FY | 367.15 Million INR | -2.71% |
| 2008 FY | 377.38 Million INR | 20.78% |
| 2007 FY | 312.45 Million INR | 49.85% |
| 2006 FY | 208.51 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 8.16 Billion INR | 98.256% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 68.356% |
| Sigachi Industries Limited | 571.8 Million INR | 75.111% |
| Bal Pharma Limited | 73.92 Million INR | -92.518% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 96.619% |
| Medico Remedies Limited | 82.9 Million INR | -71.65% |
| Lasa Supergenerics Limited | -217.3 Million INR | 165.49% |
| Venus Remedies Limited | 284.9 Million INR | 50.049% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 103.675% |
| Alpa Laboratories Limited | 167.76 Million INR | 15.171% |
| Nectar Lifesciences Limited | 49.95 Million INR | -184.911% |
| Shilpa Medicare Limited | 318.74 Million INR | 55.352% |
| Aarti Drugs Limited | 1.71 Billion INR | 91.698% |
| Lupin Limited | 19.14 Billion INR | 99.257% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.551% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.631% |
| Windlas Biotech Limited | 581.87 Million INR | 75.542% |
| Suven Life Sciences Limited | -1.05 Billion INR | 113.544% |
| Eris Lifesciences Limited | 3.91 Billion INR | 96.369% |
| Valiant Laboratories Limited | 3.19 Million INR | -4352.847% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 97.425% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 102.508% |
| Ipca Laboratories Limited | 5.47 Billion INR | 97.4% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 81.139% |
| Achyut Healthcare Limited | 5.73 Million INR | -2382.781% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.851% |
| Bajaj HealthCare Limited | -837.93 Million INR | 116.984% |
| RPG Life Sciences Limited | 876.6 Million INR | 83.765% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.256% |
| Laurus Labs Limited | 1.6 Billion INR | 91.136% |
| Piramal Pharma Limited | 178.2 Million INR | 20.139% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 43.781% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.141% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 97.689% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.948% |
| Unichem Laboratories Limited | -704.74 Million INR | 120.194% |
| Sequent Scientific Limited | -358.69 Million INR | 139.676% |
| Novartis India Limited | 851.9 Million INR | 83.295% |
| Wanbury Limited | 559.56 Million INR | 74.567% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 95.261% |
| Wockhardt Limited | -4.63 Billion INR | 103.074% |
| Themis Medicare Limited | 435.23 Million INR | 67.302% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 36.646% |
| Jubilant Pharmova Limited | 771 Million INR | 81.542% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 96.978% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.744% |
| Divi's Laboratories Limited | 16 Billion INR | 99.111% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.975% |
| Gufic Biosciences Limited | 861.35 Million INR | 83.478% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 89.414% |
| Procter & Gamble Health Limited | 2 Billion INR | 92.919% |
| FDC Limited | 3.05 Billion INR | 95.337% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 172.136% |
| Granules India Limited | 4.05 Billion INR | 96.489% |
| Medicamen Biotech Limited | 109.31 Million INR | -30.192% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.208% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 91.189% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -1906.669% |
| Brooks Laboratories Limited | -195.91 Million INR | 172.639% |
| Megasoft Limited | -127.46 Million INR | 211.648% |
| ZIM Laboratories Limited | 172.46 Million INR | 17.482% |
| Strides Pharma Science Limited | -706.14 Million INR | 120.154% |
| Neuland Laboratories Limited | 3 Billion INR | 95.257% |
| Morepen Laboratories Limited | 961.59 Million INR | 85.2% |
| Hikal Limited | 696.02 Million INR | 79.553% |
| Indoco Remedies Limited | 984.6 Million INR | 85.546% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 93.439% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 2.535% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 256.876% |
| Hester Biosciences Limited | 188.89 Million INR | 24.658% |